Results 161 to 170 of about 19,123,678 (263)

Optimal LDL-C Levels for Ischemic Stroke Prevention: A Neurologist's Perspective. [PDF]

J Lipid Atheroscler
Yang W.
europepmc   +1 more source

Clinical Impact of Adherence to Fractional Flow Reserve Guidance in Acute Coronary Syndrome

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Fractional flow reserve (FFR) is established to guide revascularization in stable coronary disease and non‐culprit lesions in acute coronary syndromes (ACS). However, real‐world adherence to FFR guidance across the spectrum of ACS presentations, including ambiguous culprit scenarios, remains incompletely characterized.
Eun Ho Choo, Ik Jun Choi, Sungmin Lim, Donggyu Moon, Dae‐Won Kim, Kiyuk Chang   +5 more
wiley   +1 more source

Elevated LDL-C and Lipoprotein(a) Modify Alirocumab Effects on CAV: Insights From the CAVIAR Trial. [PDF]

JACC Heart Fail
Terada K, Takahashi K, Khush KK, Nishi T, Knowles JW, Skoda A, Varr B, Woo C, Honda Y, Fearon WF.   +9 more
europepmc   +1 more source

Five‐Year Clinical Outcomes of Biodegradable Versus Durable Polymer Drug‐Eluting Stents: A Propensity Score‐Matched Analysis of 4394 Patients

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Biodegradable‐polymer (BP) drug‐eluting stents (DES) were developed to mitigate potential late adverse events related to persistent durable polymers in durable‐polymer (DP) DES; however, contemporary long‐term real‐world comparative data remain limited. Aims We aimed to compare the 5‐year clinical outcomes of contemporary BP‐DES and
Yangyoun Lee, Hong‐Seok Lim, Kyoung‐Woo Seo, Hyoung‐Mo Yang, So‐Yeon Choi, Seung‐Jea Tahk, Myeong‐Ho Yoon   +6 more
wiley   +1 more source

Extreme Cardiovascular Risk and LDL-C Target Achievement in People With HIV. [PDF]

Open Forum Infect Dis
Giacomelli A, Ridolfo AL, Oreni L, Carrozzo G, Cossu MV, Moschese D, Pozza G, Iannone V, Poloni A, Maggioni AP, Gori A, Gervasoni C.   +11 more
europepmc   +1 more source

Triglyceride Polygenic Score Identifies Individuals Who May Respond Differently to Aspirin in Primary Prevention

Clinical Pharmacology &Therapeutics, EarlyView.
Low‐dose aspirin is no longer routinely recommended for the primary prevention of cardiovascular disease in older adults due to a lack of net benefit over bleeding risk. We hypothesized that genetic subgroups may experience differential harm or benefit from aspirin therapy.
Peter D. Fransquet, Chenglong Yu, Cammie Tran, Sultana Monira Hussain, Chad A. Bousman, Mark R. Nelson, Andrew M. Tonkin, John J. McNeil, Paul Lacaze   +8 more
wiley   +1 more source

Current and Future Perspectives of LDL-C Lowering Therapies 2026. [PDF]

J Atheroscler Thromb
Tada H, Sakata K, Usui S, Takamura M.
europepmc   +1 more source

In Silico Clinical Trials in Drug Development: Virtual Patients, Applications, and Regulatory Convergence

Clinical Pharmacology &Therapeutics, EarlyView.
Conventional clinical trials remain the benchmark for evaluating therapeutic safety and efficacy, yet they are constrained by escalating costs, withdrawal over the extended follow‐up periods, recruitment difficulties, ethical limits, and a restricted ability to characterize heterogeneous populations.
Maximilian Balmus, Sheng‐Ya Wang, Edward W. G. Ashton, Rosie K. Barrows, Molly Monks, Yuzhang Ge, Arthur Lefebvre, Steven A. Niederer   +7 more
wiley   +1 more source

Two Sides of the Same Curve: Targets, Reduction, and LDL-C Burden. [PDF]

J Atheroscler Thromb
Ogura M.
europepmc   +1 more source

Impact of Drone Versus Car Transport on Anti‐Doping Sample Integrity Over Short Distances: A Proof‐Of‐Concept Study

Drug Testing and Analysis, EarlyView.
This proof‐of‐concept study evaluated the impact of short‐distance drone transport on anti‐doping sample integrity compared with traditional car transport. Targeted assays and untargeted metabolomics revealed equivalent biological profiles between methods, confirming that drone delivery preserves sample integrity for the athlete biological passport ...
I. Al‐Mohannadi, M. Y. Al‐Jaber, M. Al‐Nesf, W. Samsam, Abdulaziz Farooq, N. M. Thomas, M. Stuart, N. Robinson, G. Zangenfeind, D. Rovira, N. Mohamed‐Ali, A. Beotra, V. Mohamed‐Ali, M. Al‐Maadheed   +13 more
wiley   +1 more source